Clinical Trial Update: Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase II trial update on Ficerafusp Alfa in combination with Nivolumab for platinum-refractory head and neck squamous cell carcinoma; the study is not yet recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Ficerafusp Alfa (ficerafusp alfa)
• nivolumab (nivolumab)

Snippet

Sponsor: Groupe Oncologie Radiotherapie Tete et Cou | Conditions: Squamous Cell Carcinoma of Head and Neck (SCCHN) | Phase 2 | Status: NOT_YET_RECRUITING